Premier Alternatives

Zenitar Biomedical

Chengdu, China · Founded 2019 · In IPO Registration

Developer of innovative biopharmaceutical technologies designed to accelerate the discovery and commercialization of new drugs. Zenitar Biomedical is based in Chengdu, China and was founded in 2019. Its last reported valuation was $479 million in Nov 2025. It has raised $165 million.

Last reported valuation
$479.0M
Oct 2026
Priced at
—
Total raised
$165.1M
Last round
—

Zenitar Biomedical key facts

as of Oct 2026
  • Developer of innovative biopharmaceutical technologies designed to accelerate the discovery and commercialization of new drugs.
  • Zenitar Biomedical is valued at approximately $479.0M as of Oct 2026 (last reported valuation).
  • It has raised $165.1M; the latest was IPO in Jan 2026.
  • Notable investors include Qiming Venture Partners, 5Y Capital, Lanchi Ventures, Tencent Investment, Orinno Capital — 27 tracked in total.
  • Status: In IPO Registration.
Last reported valuation
LOW confidence
$479.0M

Zenitar Biomedical's last reported valuation, Nov 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Zenitar Biomedical with a free account
  • ·The complete investor list: 27 names
  • ·Watch Zenitar Biomedical: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Zenitar Biomedical funding rounds

No rounds on record

No funding rounds for Zenitar Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Zenitar Biomedical valuation

Zenitar Biomedical's last reported valuation was $479 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.

Zenitar Biomedical investors

27 investors are on record for Zenitar Biomedical, including Qiming Venture Partners, 5Y Capital, Lanchi Ventures and Tencent Investment.

About Zenitar Biomedical

Developer of innovative biopharmaceutical technologies designed to accelerate the discovery and commercialization of new drugs. The company offers comprehensive drug R&D platform covering target research, molecule design, preclinical evaluation, and clinical development, supported by resources from the State Key Laboratory of Biotherapy and Guizhou Bailing Group, thereby helping healthcare providers and patients access advanced therapies, enabling breakthroughs in disease treatment and improved clinical outcomes.

Sector
Healthcare
HQ
Chengdu, China
Founded
2019
Employees
71
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.